Literature DB >> 28170477

OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence-Reply.

Cindy L Amundsen1, Holly E Richter2, Dennis Wallace3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28170477      PMCID： PMC5534324          DOI： 10.1001/jama.2016.19566

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.

Authors:  Roger Dmochowski; Christopher Chapple; Victor W Nitti; Michael Chancellor; Karel Everaert; Catherine Thompson; Grace Daniell; Jihao Zhou; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

2.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

3.  Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

Authors:  Victor W Nitti; David Ginsberg; Karl-Dietrich Sievert; David Sussman; Sidney Radomski; Peter Sand; Dirk De Ridder; Brenda Jenkins; Andrew Magyar; Christopher Chapple
Journal:  J Urol       Date:  2016-03-30       Impact factor: 7.450
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.